CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL

Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients

Cutting-edge cancer care at the Miami Cancer Institute

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma

Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma

NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer?

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer

CheckMate-142: Updated data from MSI high metastatic colon cancer patients

Margetuximab for the treatment of HER2-positive breast cancer

The future of PARP inhibitors in metastatic breast cancer